Longevity Health (XAGE) Stock Price, News & Analysis

Company Overview

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

Key Stats

• Today's Range: $2.33 to $2.43
• 50-Day Range: N/A
• 52-Week Range: $2.20 to $38.10
• Volume: 7,764 shs
• Average Volume: 1.07 million shs
• Market Capitalization: $2.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

XAGE Stock Analysis - Frequently Asked Questions

How have XAGE shares performed this year?

Longevity Health's stock was trading at $2.59 at the start of the year. Since then, XAGE stock has decreased by 14.7% and is now trading at $2.21.

Who are Longevity Health's major shareholders?

Top institutional investors of Longevity Health include Bank of Montreal Can (1.20%).

How do I buy shares of Longevity Health?

Shares of XAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Surgical, Medical, And Dental Instruments And Supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:XAGE
• CIK: 1842939
• Web: N/A
• Phone: (412) 894-8248
• Fax: N/A
• Employees: 14
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.37 million
• Net Margins: -1,535.11%
• Pretax Margin: -1,552.42%
• Return on Equity: N/A
• Return on Assets: -280.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.42
• Quick Ratio: 0.21

Sales & Book Value

• Annual Sales: $560.67 thousand
• Price / Sales: 3.96
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($6.77) per share
• Price / Book: -0.33

Miscellaneous

• Outstanding Shares: 1,004,000
• Free Float: 713,000
• Market Cap: $2.22 million
• Optionable: N/A
• Beta: 0.51